

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



瑋俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

INSIDE INFORMATION WINDING UP PETITION

This announcement is made by the board of directors (the “**Board**”) of Wai Chun Bio-Technology Limited (the “**Company**”) pursuant to Rules 13.09 and 13.25(1)(b) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

On 29 September 2023, the Company received a winding-up petition (the “**Petition**”) filed by JAN Financial Press Limited (the “**Petitioner**”), issued with the Court of First Instance of the High Court of the Hong Kong Special Administrative Region (the “**High Court of Hong Kong**”) for the winding-up of the Company under the provisions of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), in relation to demand for the settlement of expenses and interest accrued in the aggregate amount of HK\$333,502.

The filing of the Petition with the High Court of Hong Kong only as an application for the winding-up of the Company. No winding-up order has been granted by the High Court of Hong Kong to wind up the Company. The first hearing of the Petition is scheduled to be heard on 6 December 2023 at 10:00 a.m. at the High Court of Hong Kong.

FURTHER ACTION TO BE TAKEN BY THE COMPANY

The Board is in view of the Petitioner was charging duplicate fees and the Company had requested face-to-face meetings with the Petitioner time after time so that the Petitioner could explain and clarify the relevant charges. Unfortunately, the Petitioner always refused to attend the meetings.

In view of the above, the Company is in the course of seeking legal advice for determining the possible actions in respect of the Petition to protect the interests of the Company and its shareholders as a whole. The Company reserves all rights to take any legal actions to prosecute the legal liabilities of the Petitioner as the Petitioner intends to disrupt the Company’s normal business operations by liquidation petition.

IMPACT OF THE PETITION TO THE COMPANY

As at the date of this announcement, to the best of the directors' knowledge, information and belief, the Petition has had no any impact to the business operation and financial position of the Company and its subsidiaries. There is also not a possibility that the Company will be issued a winding-up order by the High Court of Hong Kong due to such a small fee dispute.

There is no other outstanding winding up petition filed against the Company as at the date of this announcement.

The Company will make further announcement(s) to keep its shareholders and investors informed of any significant developments in relation to the Petition as and when appropriate.

By order of the Board
Wai Chun Bio-Technology Limited
LAM KA CHUN
Executive Director

Hong Kong, 25 October 2023

As at the date of this announcement, the Board consists of one executive Director, namely Mr. Lam Ka Chun and two independent non-executive Directors, namely Ms. Hong Ting and Mr. Wan Bo.